In this paper we have tested pole-climbing time in Parkinson's disease mice, determined the levels of DA and HVA in striatum, analyzed the levels of dopamine receptor 1 and dopamine receptor 2 in striatum and the level of Caspase-3 protein in substantia nigra, by which we can investigate the mechanism of extract of Acanthopanax
senticosus Harms against Parkinson's disease.
Many previous research showed that acanthopanax
senticosus (AS) and its extract were promising and safe candidates in antimicrobial and anti-stress studies (Han et al.
1) isolated from the root bark of Acanthopanax
DFH controls 70% of all wild Acanthopanax
resources in China and also owns an herbal extraction plant that processes raw Acanthopanax
This was attributed to sales of its Acanthopanax
products, which accounted for about 51% of the total revenues
Renhuang presented its leading branded drug, Acanthopanax
(Siberian Ginseng), and the scientific research on it.
ABSTRACT : This study was conducted to test the hypothesis that dietary supplementation with an herbal extract of Acanthopanax
senticosus (AS) enhances the immune response in weaned piglets.
spinosa TCM35 Herba Leonuri Leonurus heterophyllus TCM36 Radix Acanthopanacis senticosi Acanthopanax
senticosus TCM37 Caulis Bambusae in taeniam Bambusa tuldoides TCM38 Herba Menthae Mentha haplocalyx TCM39 Flos Daturae Datura metel TCM40 Herba Ajugae AJuga decumbens TCM41 Aloe Aloe vera TCM42 Herba Equisetihiemalis Equisetum hiemale TCM43 Rhizoma Paridis Paris polyphylla var.
The increase was primarily driven by continued strong sales in Acanthopanax
medical products, Shark Power Health Care products, and Traditional Medical products, which respectively contributed 53%, 12%, and 35% to the total revenues.
Renhuang presented the study results on its leading branded drug, Acanthopanax
(Siberian Ginseng), which treats sleep disorders and depression by reducing tension and putting individuals in a more relaxed state.
senticosus; Siberian ginseng) exhibits pronounced effects on the symptoms of common colds and influenza-like diseases (Elkin et al.
OB), a leading provider of natural health care products in the People's Republic of China (PRC), today announced the approval by the Russian FDA of its Acanthopanax